01846 EUROEYES
- 5.820
- +0.060+1.04%
EUROEYES News
Deshijia (01846) spent HK$548,800 to buy back 100,000 shares on May 2
Deshijia (01846) announced that on May 2, 2024, the company spent HK$548,800 to repurchase 1...
EuroEyes International to Buy Back Up to 3% Shares
EuroEyes International Eye Clinic (HKG:1846) intends to buy back up to around 10 million, or 3%, shares of the company, a Friday filing on the Hong Kong bourse stated. The share repurchase will be con
Deshijia (01846.HK): Intended to buy back shares in the market
On April 26, GLONGHUI (01846.HK) issued an announcement. On April 26, 2024, the board of directors officially decided to use the repurchase authorization. Depending on market conditions, the company may repurchase up to 3% of the total number of shares issued on the open market on the date of this announcement (that is, no more than 9.9972 million shares based on 333 million shares already issued on May 31, 2023). The company will fund the proposed repurchase from its internal financial resources.
德視佳：2023年年報
EuroEyes International Logs 6% Growth in Q1 Eye Surgeries
EuroEyes International Eye Clinic (HKG:1846) performed 7,234 eye surgeries in the first quarter of 2024, up 6% from the year-ago figure of 6,825, a Tuesday filing on the Hong Kong bourse stated. The e
Deshijia (01846.HK): Total number of eye surgeries increased 6% year-on-year in the first quarter
On April 23, Ge Longhui (01846.HK) announced that in the first quarter of 2024, the total number of ophthalmic surgeries performed by the Group was 7,234, an increase of 6% over the same period in 2023. The Group's sales mix continued to change favourably throughout the first quarter of 2024 due to (i) a significant increase in the number of crystal replacement surgeries; and (ii) the opening of clinics in Hong Kong and London, which led to significant revenue growth. The Board considers this to be in line with the Group's three-year endogenous compound annual growth rate (CAGR) guidelines.
EUROEYES To Go Ex-Dividend On June 11th, 2024 With 0.0489 HKD Dividend Per Share
April 2nd - $EUROEYES(01846.HK)$ is trading ex-dividend on June 11th, 2024. Shareholders of record on June 12th, 2024 will receive 0.0489 HKD dividend per share on June 28th, 2024. The ex-dividend
Deshijia (01846) will pay a final dividend of HK$0.0489 per share on June 28
Deshijia (01846) announced that the company will pay a final dividend of 0.0 per share on June 28, 2024...
Deshijia (01846) announced annual results, with profit of HK$133 million, an increase of 59.6% over the previous year
According to the Zhitong Finance App, Dexijia (01846) announced results for the year ended December 31, 2023, with revenue of approximately HK$714 million, up 17% year on year; profit of HK$133 million during the year, up 59.6% year on year; basic profit per share was 39.544 cents, with a proposed final dividend of HK$0.0489 per share. According to the announcement, the Group's revenue and gross profit reached record highs of HK$714.3 million and HK$336 million respectively in the current fiscal year, with year-on-year increases of 17.0% and 23.9%, respectively. Gross margin also increased 2.6 percentage points to 47.0%. Group experience
EUROEYES: ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Deshijia (01846.HK) held a board meeting on March 28 to review and approve the annual results
Glonghui, March 15, 丨 Dexijia (01846.HK) announced that the company will hold a board meeting on March 28, 2024 (Thursday) to review and approve the annual results and publication of the company and its subsidiaries for the year ended 31 December 2023, and to consider the proposed payment of a final dividend (if applicable).
EUROEYES: DATE OF BOARD MEETING
Announcement Highlights | NIO's Q4 revenue increased 6.5% year on year to 17.103 billion yuan; Great Wall Motor's February sales increased 4.12% year on year
China Electric Power's combined total electricity sales volume in January was 10.3482 million megawatt-hours, an increase of 41.15% over the previous year; Shanghai Pharmaceutical: Norepinephrine bitartrate injection passed the generic drug consistency evaluation.
EuroEyes International Forecasts Boost in 2023 Profit
EuroEyes International Eye Clinic (HKG:1846) expects an attributable profit of between approximately HK$128 million and HK$135 million for the year 2023, up from HK$89.5 million in 2022, a Tuesday fil
Dexijia (01846.HK) Profit: Expected annual net profit of about HK$128 million - HK$135 million HK$89.5 million in the same period last year
On March 5, GLONGHUI (01846.HK) announced that the Group is expected to record: (i) profit attributable to the owners of the company ranged from about HK$128 million to HK$135 million, compared with about HK$89.5 million last year; and (ii) profit before interest, tax, depreciation and amortization for the year was approximately HK$278 million to HK$290 million, an increase of about 30% to 36% over the previous year's approximately HK$214 million. The Board believes that compared to last year, the increase in profit attributable to company owners and profit before interest, tax, depreciation and amortization expectations for this year is mainly due to: (i) after COVID-19 restrictions were lifted
EUROEYES: POSITIVE PROFIT ALERT
Insider Spends HK$478k Buying More Shares In EuroEyes International Eye Clinic
Whilst it may not be a huge deal, we thought it was good to see that the EuroEyes International Eye Clinic Limited (HKG:1846) VP of Denmark & Executive Director, Jannik Jørgensen, recently bought HK$4
EuroEyes Reports 14% Increase In Q4 Surgeries
EuroEyes International Eye Clinic (HKG:1846) said it conducted 7,286 eye surgeries during the quarter through December, 2023, representing an increase of 14% over the same period of 2022. The clinic c
The total number of eye surgeries performed by Deshijia (01846.HK) in 2023 was 283,000, an increase of 12% year-on-year
Gelonghui, January 16, 丨 Deshijia (01846.HK) announced that the total number of eye surgeries performed in the fourth quarter of 2023 was 7,286, an increase of 14% over the same period in 2022 (from October 1, 2022 to December 31, 2022:6,380 cases). The total number of eye surgeries performed in the year ended 31 December 2023 was 28,294, an increase of 12% over the same period in 2022 (year ended 31 December 2022:25,245 cases).
Jörn Jörgensen Buys Handful Of Shares In EuroEyes International Eye Clinic
Those following along with EuroEyes International Eye Clinic Limited (HKG:1846) will no doubt be intrigued by the recent purchase of shares by Jörn Jörgensen, Founder of the company, who spent a sto
Analysis
Price Target
No Data
